TCR αβ+/CD19+ Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Malignant and Non-malignant Disorders

Condition:   Allogeneic Hematopoietic Cell Transplantation Intervention:   Drug: TCRαβ+/CD19+ depleted allogeneic hematopoietic stem cell transplant (HSCT) Sponsor:   Children's Hospital Medical Center, Cincinnati Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials